



**FY 2023**  
**Second Quarter Report**  
**October – December 2022**

---



Arkansas Department of Health

# BreastCare Quarterly Report

## October-December Fiscal Year 2023



Funded by the Arkansas Department of Health (ADH) with support from the Centers for Disease Control and Prevention (CDC) and Arkansas Tobacco Excise Tax.

**Table 1: Number of Women Enrolled<sup>1</sup>, FY 2023**

Funding Source	Number of Women Enrolled October-December, FY 2023	Number of Women Enrolled To-Date, FY 2023
<b>Total</b>	2,726	5,454
<b>Federal</b>	1,700	3,379
<b>State</b>	1,026	2,075

Data source: FY 2023 BreastCare Online System Data.

<sup>1</sup>Unduplicated count of women enrolled in the BreastCare Program during the period.

**Table 2: BreastCare Funds by Expenditures and Percent Spent on Clinical Services, FY 2023**

Month	October	November	December	October-December Average	Monthly Average To-Date FY 2023
<b>Total Expenditures</b>	\$429,512	\$423,517	\$390,784	\$414,604	\$393,617
<b>Expenditures on Clinical Services</b>	\$332,388	\$286,860	\$268,720	\$295,989	\$285,239
<b>Percent of Expenditures Spent on Clinical Services</b>	77.4%	67.7%	68.8%	71.4%	72.5%

Data Source: Monthly BreastCare Financial Status Report

**Table 3: Number and Percent of Screenings Performed, FY 2023**

Provider Type	Number of Screenings <sup>1</sup> , Oct-Dec, FY 2023	Number of Screenings <sup>1</sup> , To-Date, FY 2023	Percent of Screenings, FY 2023
Health Department Clinic	1,817	3,727	56.4%
Community Health Center	632	1,152	17.4%
Hospital	739	1,419	21.5%
Private Provider	169	315	4.7%
<b>Total<sup>1</sup></b>	<b>3,357</b>	<b>6,613</b>	<b>100.0%</b>

Data source: FY 2023 BreastCare Online System Data.

<sup>1</sup>Unique screening tests performed during the period. Screening tests include clinical breast exams, screening mammograms, and Pap tests.

**Table 4: Number of Screening Tests Performed through BreastCare, FY 2023**

Type of Test	Number of Tests Performed Oct-Dec, FY 2023	Number of Tests Performed To-Date, FY 2023
Clinical Breast Exam <sup>1</sup>	1,152	2,257
Mammograms <sup>2</sup>	885	1,687
Pap Tests <sup>3</sup>	1,320	2,669

Data source: FY 2023 BreastCare Online System Data.

<sup>1</sup>Number of clinical breast exam performed during the period, clients may receive more than one clinical breast exam.

<sup>2</sup>Number of screening mammograms performed during the period, clients may receive more than one screening mammogram.

<sup>3</sup>Number of Pap tests performed during the period, clients may receive more than one Pap test.

**Table 5: Mammogram Screening History at Enrollment, Women 40 – 64 years old, FY 2023**

Last Mammogram	Percent of Enrollees Oct-Dec, FY 2023	Percent of Enrollees To-Date, FY 2023
Within 2 Years	42.9%	42.7%
More than 2 Years	29.5%	29.5%
Never Had Mammogram	27.6%	27.8%

**Table 6: Number of Cancer and Precancer Diagnoses Reported among BreastCare Women, FY 2023**

Type of Diagnosis	Number of Diagnoses October-December, FY 2023		Number of Diagnoses To-Date FY 2023	
	Total	(Age < 40)	Total	(Age < 40)
<b>Breast Cancer<sup>1</sup></b>	12	(3)	21	(13)
<b>In Situ Breast Cancer<sup>2</sup></b>	0	(0)	5	(1)
<b>Cervical Cancer<sup>3</sup></b>	2	(2)	2	(2)
<b>Cervical Precancer<sup>4</sup></b>	9	(7)	27	(17)
<b>Hyperplasia<sup>5</sup></b>	4	(0)	9	(0)
<b>Atypical Hyperplasia<sup>6</sup></b>	2	(0)	3	(0)

Data source: FY 2023 BreastCare Online System (BOS) Data

<sup>1</sup>Unduplicated count of women with a final diagnosis of invasive breast cancer reported in BOS during the period.

<sup>2</sup>Unduplicated count of women with a final diagnosis of in situ breast cancer (DCIS/LCIS) reported in BOS during the period.

<sup>3</sup>Unduplicated count of women with a final diagnosis of invasive cervical cancer reported in BOS during the period.

<sup>4</sup>Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2/CIN-3) reported in BOS during this period.

<sup>5</sup>Unduplicated count of women with a biopsy diagnosis of hyperplasia reported in BOS during the period.

<sup>6</sup>Unduplicated count of women with a biopsy diagnosis of atypical hyperplasia reported in BOS during the period.

**Table 7: BreastCare Funds by Funding Source (Revenue and Expenditures) and Percent Spent on Clinical Services, FY 2020-2023**

Funding Source	FY 2020	FY 2021	FY 2022	FY 2023 (Budgeted)
<b>Federal</b>				
<b>Revenue</b>	\$1,700,000	\$1,700,000	\$1,700,000	\$2,500,000
<b>Expenditures</b>	\$1,637,220	\$1,553,049	\$1,599,714	\$2,500,000
<b>State</b>				
<b>Revenue</b>	\$3,202,990	\$3,224,579	\$3,195,344	\$3,088,494
<b>Expenditures</b>	\$2,710,321	\$3,217,868	\$3,415,132	\$3,088,494
<b>Percent of Expenditures Spent on Clinical Services</b>	72%	65%	72%	70%

Data Source: BreastCare Monthly Budget Report

**Table 8: BreastCare Clinical Services<sup>1</sup> Expenditures by Funding Source, FY 2020-2023**

Funding Source	FY 2020	FY 2021	FY 2022	FY 2023 (Budgeted)
Federal Grant	\$1,324,515	\$1,272,753	\$1,361,448	\$1,594,000
State Tobacco Excise Tax	\$1,817,189	\$1,809,999	\$1,908,096	\$1,868,000
<b>Total</b>	<b>\$3,141,704</b>	<b>\$3,082,752</b>	<b>\$3,269,544</b>	<b>\$3,462,000</b>
<b>Total Number of Women Served</b>	<b>9,026</b>	<b>8,411</b>	<b>9,339</b>	<b>9,805</b>
<b>Average Cost of Each Woman Served</b>	<b>\$348.07</b>	<b>\$366.51</b>	<b>\$350.10</b>	<b>\$353.09</b>

Data source: BreastCare Budget

<sup>1</sup>Clinical Services - Direct service provided to women who enroll in the program. These services consist of screening, diagnostic and case management services as well as salaries for Nurse Practitioners and Public Health Nurses who provide one-on-one services.

**Table 9: Clinical Services Provided by BreastCare Funding Sources, FY 2022**

Funding Source	Number of Women Enrolled <sup>1</sup> (% of total)	Number of Women Served <sup>2,4</sup> (% of total)	Number of Women Screened <sup>3,4</sup> (% of total)
Federal	6,589	5,523	5,266
State	4,046	3,816	3,666
<b>Total</b>	<b>10,635</b>	<b>9,339</b>	<b>8,932</b>

Data Source: FY 2022 BreastCare Online System Data

<sup>1</sup>Unduplicated count of women enrolled into BreastCare during the period.

<sup>2</sup>Unduplicated count of women receiving any clinical service through BreastCare during the period. Clinical services are related to breast and cervical cancers including screening and diagnostic procedures.

<sup>3</sup>Unduplicated count of women who received any screening procedure through BreastCare during the period. Screening procedures include clinical breast exams, mammograms and Pap tests.

<sup>4</sup>Numbers may change based on billing cycles and delays.

## **Definitions Used in This Report:**

### **Updated: October, 2022**

1. **Women enrolled:** Unduplicated count of women enrolled into the ADH BreastCare Program during a specified time period; *Source of report: BreastCare Online System.*
2. **Women served:** Unduplicated count of women receiving any clinical service through BreastCare Program during a specified time period. Clinical services include screening and diagnostic procedures; *Source of report: BreastCare Online System.*
3. **Women screened:** Unduplicated count of women receiving any screening procedure through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, screening mammogram, and Pap test; *Source of report: BreastCare Online System.*
4. **Screenings by provider type:** Unduplicated count of screening procedures through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, conventional mammogram, digital mammogram, conventional Pap test, and liquid-based Pap test; *Source of report: BreastCare Online System.*
5. **Clinical Breast Exams performed:** Number of clinical breast exams provided by BreastCare Program, sometimes more than one for the same client, during a specific time period; *Source of Report: BreastCare Online System.*
6. **Mammograms performed:** Number of screening mammograms provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; *Source of Report: BreastCare Online System.*
7. **Pap tests performed:** Total number of Pap tests provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; *Source of Report: BreastCare Online System.*
8. **Breast cancer diagnosis:** Unduplicated count of women with a final diagnosis of invasive breast cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System.*
9. **In Situ Breast cancer diagnosis:** Unduplicated count of women with a final diagnosis of in situ breast cancer (DCIS/LCIS) reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System.*
10. **Cervical cancer diagnosis:** Unduplicated count of women with a final diagnosis of invasive cervical cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System.*
11. **Cervical precancer diagnosis:** Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2 or CIN-3) reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*

12. Hyperplasia diagnosis: Unduplicated count of women with a final diagnosis of hyperplasia reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*
13. Atypical hyperplasia diagnosis: Unduplicated count of women with a final diagnosis of atypical ductal hyperplasia reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*